Bexson Biomedical
Dr. Wallach is a medicinal chemist with world recognized expertise in NMDA receptor pharmacology. As faculty at the University of the Sciences in Philadelphia, his research includes characterizing dissociative and psychedelic class chemistry, he has synthesized over 100 novel compounds, and has published numerous articles and book chapters. Dr. Wallach heads Bexson’s discovery division, helping develop the chemical basis behind Bexson’s three lead ketamine candidates for subcutaneous delivery, and efforts to synthesize new chemical entities with a polypharmacology approach. Dr. Wallach’s research in drug development spans a wide range of valuable therapeutic areas, including neuropathic pain, neurodegenerative diseases, depression and cancer.
This person is not in any offices
Bexson Biomedical
2 followers
Bexson Biomedical is developing non-opioid therapies for pain management. Their goal is to provide therapies that provide relief to patients and reduce the rates of opioid addiction.